In conclusion, although further studies are needed to confirm these results and reclassify these AMLs in the intermediate or even favorable group of the 2022 ELN risk classification, our study showed that the combination of imatinib and standard intensive chemotherapy should be recommended in fit patients with de novo BCR::ABL1+ AML. The gene discussed is ABL1; the disease is acute myeloid leukemia.